172.51
price down icon0.79%   -1.37
after-market Handel nachbörslich: 172.51
loading

Repligen Corp Aktie (RGEN) Neueste Nachrichten

pulisher
Oct 12, 2026

RGEN5964422 Bond Profile: Coupon and Redemption - TradingView

Oct 12, 2026
pulisher
Oct 10, 2026

Repligen Corp (BSP:R2GE34) Stock HoldersInstitutional & Insider Ownership - GuruFocus

Oct 10, 2026
pulisher
Oct 09, 2026

Is It Too Late to Buy Repligen Corp (RGEN) After 6.1% Rally? GF Value Says Undervalued - GuruFocus

Oct 09, 2026
pulisher
Oct 09, 2026

Repligen Corp (RGEN) Insider Trading Activity | Apple Insider Buys and Sells - GuruFocus

Oct 09, 2026
pulisher
Oct 09, 2026

Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance

Oct 09, 2026
pulisher
Oct 08, 2026

A 700-share stock grant joins options with a $174.86 exercise price for Repligen (RGEN)’s chief product officer. - Stock Titan

Oct 08, 2026
pulisher
Oct 08, 2026

Repligen Corp at Leerink Global Healthcare Conference Transcript - GuruFocus

Oct 08, 2026
pulisher
Oct 07, 2026

One holder reports no voting power in Repligen (RGEN), despite a 7.36M-share passive stake. - Stock Titan

Oct 07, 2026
pulisher
Oct 07, 2026

Repligen CEO Olivier Loeillot sells $1.03m of company stock By Investing.com - Investing.com Nigeria

Oct 07, 2026
pulisher
Oct 06, 2026

Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,535 Shares - GuruFocus

Oct 06, 2026
pulisher
Oct 06, 2026

Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tel - GuruFocus

Oct 06, 2026
pulisher
Oct 06, 2026

Repligen CEO Olivier Loeillot sells $1.03m of company stock - Investing.com

Oct 06, 2026
pulisher
Oct 06, 2026

Repligen (RGEN) CEO sells shares at $190 and $178.75 under a preset trading plan. - Stock Titan

Oct 06, 2026
pulisher
Oct 06, 2026

Repligen Closes BioLife Solutions Acquisition - Yahoo Finance

Oct 06, 2026
pulisher
Oct 06, 2026

Repligen completes acquisition of BioLife Solutions - Investing.com

Oct 06, 2026
pulisher
Oct 06, 2026

18 commercially approved therapies are supported by BioLife's cell-preserving media. Repligen completed the deal. - stocktitan.net

Oct 06, 2026
pulisher
Oct 06, 2026

Repligen Completes Acquisition of BioLife Solutions - Yahoo Finance

Oct 06, 2026
pulisher
Oct 06, 2026

Form 144 REPLIGEN CORP For: 5 October By Investing.com - Investing.com South Africa

Oct 06, 2026
pulisher
Oct 05, 2026

Repligen Corp (RGEN) Stock Up 4.3% but GF Value Says Overvalued -- GF Score: 85/100 - GuruFocus

Oct 05, 2026
pulisher
Oct 05, 2026

Loeillot proposes selling 4,202 Repligen (RGEN) shares through Fidelity. - stocktitan.net

Oct 05, 2026
pulisher
Oct 05, 2026

For stock-grant taxes, Repligen (RGEN) withholds 1,248 CEO shares at $181.70 each. - stocktitan.net

Oct 05, 2026
pulisher
Oct 05, 2026

Form 144 REPLIGEN CORP For: 5 October By Investing.com - Investing.com Nigeria

Oct 05, 2026
pulisher
Oct 05, 2026

1,333 shares vested October 2 are proposed for sale at Repligen (NASDAQ: RGEN). - stocktitan.net

Oct 05, 2026
pulisher
Oct 05, 2026

BioLife Solutions Shareholders Approve Repligen Merger Agreement - Yahoo Finance

Oct 05, 2026
pulisher
Oct 04, 2026

REPLIGEN CORP. R (RGN.MU) Q1 FY2026 earnings call transcript - Yahoo Finance

Oct 04, 2026
pulisher
Oct 01, 2026

Repligen Corporation (RGEN) Options Chain - Yahoo! Finance Canada

Oct 01, 2026
pulisher
Oct 01, 2026

Repligen Corporation (RGEN) Options Chain - Yahoo! Finance Canada

Oct 01, 2026
pulisher
Oct 01, 2026

A Look at Repligen Corp (RGEN) After 7.8% Decline -- GF Value $1 - GuruFocus

Oct 01, 2026
pulisher
Oct 01, 2026

Continuous Bioprocessing Technologies MarketGlobal Forecast 2026-2031 | Market to Reach USD 8.5 Billion as Automation and Biologics Demand Fuel 12.1% CAGR - GlobeNewswire Inc.

Oct 01, 2026
pulisher
Sep 29, 2026

Repligen stock price target reaffirmed at $225 by UBS on growth outlook - Investing.com South Africa

Sep 29, 2026
pulisher
Sep 29, 2026

Repligen stock price target reaffirmed at $225 by UBS on growth outlook - Investing.com UK

Sep 29, 2026
pulisher
Sep 29, 2026

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? - TradingView

Sep 29, 2026
pulisher
Sep 28, 2026

After a stock-unit release, Repligen (RGEN) withheld 421 shares from its CFO to cover taxes. - Stock Titan

Sep 28, 2026
pulisher
Sep 27, 2026

Repligen CEO Olivier Loeillot sells $976,680 in company stock - Investing.com

Sep 27, 2026
pulisher
Sep 26, 2026

Repligen CEO Loeillot sells $2.46m in shares - Investing.com

Sep 26, 2026
pulisher
Sep 25, 2026

Repligen Corp (RGEN) CEO Olivier Loeillot Sells 12,946 Shares - GuruFocus

Sep 25, 2026
pulisher
Sep 25, 2026

Repligen (RGEN) CEO sells shares at $190 each after exercising options under a trading plan. - Stock Titan

Sep 25, 2026
pulisher
Sep 24, 2026

Form 144 REPLIGEN CORP For: 24 September By Investing.com - Investing.com Nigeria

Sep 24, 2026
pulisher
Sep 24, 2026

Repligen Corporation (RGEN) Stock Forecasts - finance.yahoo.com

Sep 24, 2026
pulisher
Sep 24, 2026

Is Repligen Corp (RGEN) Overvalued After 3.3% Rally? GF Value Sa - GuruFocus

Sep 24, 2026
pulisher
Sep 24, 2026

Shares valued at $2.46 million are listed for sale by a Repligen (NASDAQ: RGEN) officer and director. - Stock Titan

Sep 24, 2026
pulisher
Sep 24, 2026

Repligen Corp Stock Baskets - GuruFocus

Sep 24, 2026
pulisher
Sep 23, 2026

Repligen Corp (BSP:R2GE34) Stock Price & 30 Year Financial Data - GuruFocus

Sep 23, 2026
pulisher
Sep 23, 2026

Repligen Corporation stock hits 52-week high at 188.95 USD - Investing.com

Sep 23, 2026
pulisher
Sep 23, 2026

Repligen Corporation stock hits 52-week high at 188.95 USD By Investing.com - Investing.com UK

Sep 23, 2026
pulisher
Sep 23, 2026

Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,426 Shares - GuruFocus

Sep 23, 2026
pulisher
Sep 22, 2026

Repligen Corp (RGEN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 87/100 - GuruFocus

Sep 22, 2026
pulisher
Sep 22, 2026

Repligen (RGEN) CEO sells 5,426 shares under plan - Stock Titan

Sep 22, 2026
pulisher
Sep 22, 2026

Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK

Sep 22, 2026
pulisher
Sep 22, 2026

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - Zacks Investment Research

Sep 22, 2026
COO COO
$55.55
price up icon 2.16%
$15.49
price down icon 1.15%
$140.42
price down icon 1.60%
BAX BAX
$24.78
price up icon 1.77%
ATR ATR
$118.95
price down icon 1.19%
$85.31
price down icon 2.27%
Kapitalisierung:     |  Volumen (24h):